iTeos
TIGIT Turmoil: How Pharma Burned Billions on Failed Immuno-Oncology Projects
TIGIT; immuno-oncology; failed clinical trials; pharma investment loss; Gilead; GSK; Bristol Myers Squibb; Novartis; Merck; Roche; iTeos; Arcus Biosciences; tiragolumab; belrestotug
iTeos to Shut Down Operations After TIGIT Therapy Setback
iTeos Therapeutics; TIGIT failure; GSK exit; clinical trial failure; belrestotug; asset sale; immuno-oncology; EOS-984; EOS-215; ENT1 obesity program
GSK and iTeos End Belrestotug TIGIT Program After Disappointing Lung Cancer Results
GSK; iTeos; belrestotug; TIGIT; lung cancer; dostarlimab; clinical trial; drug development; GALAXIES Lung-201; immuno-oncology; progression-free survival
Cancer Pipelines Contract: Incyte and iTeos Discontinue Drug Candidates Amid Underwhelming Clinical Results
Incyte, iTeos, cancer pipelines, drug candidates, clinical trials, disappointing data, pipeline cuts, oncology research.
iTeos Therapeutics Deprioritizes Inupadenant Despite Encouraging Phase 2 Data in NSCLC
iTeos Therapeutics, Inupadenant, Adenosine A2A Receptor Antagonist, NSCLC, Phase 2 Trial, Deprioritization
iTeos-GSK’s TIGIT Combination Demonstrates Superior Tumor Shrinkage in Phase 2 Trial
iTeos Therapeutics, GSK, TIGIT, EOS-448, Jemperli, Phase 2 trial, tumor shrinkage, immuno-oncology, cancer treatment